# Bright Minds Biosciences Inc. (DRUG) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $65.16, market value $639 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Bright Minds Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.9×**. The shares trade at 2.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -2.8%** (5-yr avg -2.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -14.9%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -173.8%**. Earnings per share fell 173.8%.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Current ratio: 36.10** (quick 36.10). Current assets cover the next year's liabilities 36.10 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Bright Minds Biosciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (3 analysts). 3 analysts cover Bright Minds Biosciences Inc.; the consensus is strong_buy, with an average price target of $169.96 (+161% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 48.3%** (YTD -16.5%, 3-mo -5.6%). The shares are up 48.3% over twelve months including dividends.
- **From 52-week high: -47.3%** (64.1% above the low). Trading 47% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 32**. An RSI of 32 is neutral.
- **Beta (1 yr): 1.79** (volatility 68%). Beta of 1.79 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DRUG · Page: https://foliofundamentals.com/stocks/drug

Not investment advice.